TryptoBPH - Proof-of-concept study to evaluate the safety and efficacy of tryptophan in patients with BPH

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519076-75-00

Acronym

TryptoBPH

Enrollment

Registered

2024-11-07

Start date

2024-12-05

Completion date

Unknown

Last updated

2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Brief summary

Change from baseline in the total score (questions 1–7) of the IPSS questionnaire

Detailed description

Urine maximum flow rate (Qmax); Erectile function, assessed by International Index of Erectile Function-5 (IIEF-5); and prostate volume (in cc), assessed by trans-rectal ultra-sound; and in quality of life due to urinary symptoms (question 8 of the IPSS)

Interventions

DRUGOmnic 0

DRUG4 mg

DRUGcomprimidos de libertação prolongada

DRUGrevestidos por película

DRUGCincofarm 100 mg Cápsulas

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in the total score (questions 1–7) of the IPSS questionnaire	—

Secondary

Measure	Time frame
Urine maximum flow rate (Qmax); Erectile function, assessed by International Index of Erectile Function-5 (IIEF-5); and prostate volume (in cc), assessed by trans-rectal ultra-sound; and in quality of life due to urinary symptoms (question 8 of the IPSS)	—

Countries

Portugal

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026